RSS
Логотип
Баннер в шапке 1
Баннер в шапке 2

Rosatom Center for Nuclear Research and Technology in Bolivia

Company


Owners:
Rosatom

Content

Owners

History

2023: Start of production of radiofampreparations

In Bolivia, they began to produce radiopharmaceuticals at the facilities built by Rosatom. The press service of the state corporation announced this on March 10, 2023.

The solemn event, timed to coincide with the start of deliveries of fluorodeoxyglucose radiopharmaceutical to Bolivian clinics, took place at the Center for Nuclear Medicine and Radiotherapy, designed to treat patients with cancer. As noted in Rosatom, a unique complex for the production of radiopharmaceuticals for Latin America was built by order of the Bolivian Atomic Energy Agency (ABEN).

Solemn event dedicated to the launch in Bolivia of the production of radiopharmaceuticals at the facilities built by Rosatom

The cyclotron complex is part of a large-scale project of Russian-Bolivian cooperation - the Center for Nuclear Research and Technology (CNRT), built in El Alto at an altitude of 4000 meters above sea level. The facility will provide the Bolivian health care system with its own production of a whole line of radiopharmaceuticals for clinical trials of more than 5,000 patients per year. It is noted that Bolivian citizens will be able to undergo a timely and high-quality medical examination with the help of advanced drugs of nuclear medicine without traveling abroad. In the future, the work of the complex will allow completely import substitution of supplies of radiopharmaceuticals for the network of Bolivian nuclear medicine centers.

According to Kirill Komarov, First Deputy Director General and Director of the Block for Development and International Business of Rosatom State Corporation, the first patients received radiopharmaceuticals created in the new cyclotron complex, and this was the first stage of joint work with Bolivian partners. The next step is to expand the line of manufactured radiopharmaceuticals and export these drugs to neighboring countries.[1]

2021: Centre launch announcement

At the end of December 2021, Rosatom announced the launch in Bolivia of a center for nuclear research and technologies for the production of radiopharmaceuticals.

File:Aquote1.png
The presence of its own production of radiopharmaceuticals will expand the capabilities of Bolivian health care and make it even more effective to fight a whole range of diseases that require high-tech medical care, "said Evgeny Pakermanov, President of RuSat Overseas JSC.
File:Aquote2.png

Rosatom launches production of radiopharmaceuticals in Bolivia

According to him, by the end of December 2021, the company is approaching the final stage in the implementation of the preclinical cyclotron-radiopharmacological complex (PCRC), which will provide Bolivian medical clinics with modern radiopharmaceuticals. By this time, test tests of the technological line for the production of fluoroglucose, a radiopharmaceutical used in positron emission tomography (PET), which allows detecting oncological diseases at an early stage, have been carried out.

By the end of December 2021, Rosatom completed tests of the technological line of the center for nuclear research and technology in Bolivia for the production of radiopharmaceuticals. Commissioning works are completed at the first facilities of the center - the preclinical cyclotron-radiopharmacological complex and the multi-purpose radiation center (MCC). More than 500 Bolivian citizens participate in the construction of the center.

It is noted that the center for nuclear research and technology is one of the most important projects in Bolivia in the field of health. Radiopharmaceuticals will be delivered to Bolivia's nuclear medicine centers and will allow diagnosis and treatment of more than 5,000 patients per year. Local residents will be able to undergo a timely and high-quality medical examination with the help of advanced drugs of nuclear medicine without traveling abroad, the press service of the state corporation notes.[2]

Notes